IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies
AdvanTIG-301 closed early with 63 patients, leaving its stage III NSCLC comparisons descriptive
Read the article
Solange Peters
CHUV, Lausanne
Prof. Solange Peters is Head of Medical Oncology at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She served as President of ESMO from 2020 to 2021 and is a leading global voice in thoracic oncology. Her research spans immunotherapy in lung cancer, targeted-therapy resistance, and biomarker-driven clinical trial design.
Connect
Solange Peters
Featured in
Aug
05
2026
S. Peters
Jul
14
2026
ADCs
Advanced NSCLCSCLCADCs
ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities
Read the article
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
Nov132026
ILCS 2026
The International Lung Cancer Summit 2026
Learn more about the event
S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniL. ByersG. MountziosA. Dingemans
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
Jun
25
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies
Immunotherapies in NSCLC
1h 47 min
P. FordeJ. RemonS. Peters
Jun
17
2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies
Small Cell Lung Cancer
1h 35 min
G. MountziosJ. SandsS. Peters
Oct
04
2024
ILCS 2024
Welcome & Introduction
6 min
S. PetersA. Addeo
Programme Roster
